GPP
ORKA

Great Point Partners’s Oruka Therapeutics ORKA Stock Holding History

Great Point Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Hold
183,330
– – 3.3% 12
2026
Q1 		$8.99M Hold
183,330
– – 2.07% 19
2025
Q4 		$5.56M Hold
183,330
– – 1.8% 22
2025
Q3 		$3.53M Buy
+183,330
New +$2.72M 1.45% 24
2025
Q1 		– Sell
-228,803
Closed -$4.44M – 36
2024
Q4 		$4.44M Sell
228,803
-285,856
-56% -$6.97M 2.09% 21
2024
Q3 		$12.6M Buy
+514,659
New +$17.9M 3.71% 11

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Great Point Partners's ORKA Position: Q2 2026 in Review

Great Point Partners held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 183,330 shares worth $17.4M. The position accounts for 3.3% of the portfolio, ranked #12.

Great Point Partners first reported a position in ORKA in Q3 2024 and has held it in 6 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Great Point Partners held 183,330 shares of Oruka Therapeutics worth $17.4M as of Q2 2026.
  • Great Point Partners left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up 3.3% of Great Point Partners's portfolio in Q2 2026, its #12 holding.
  • Great Point Partners first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.